Glaukos Corporation
NYSE:GKOSMedical - Devices
-$0.18 today
- Market cap
- $13.80B
- Beta
- 0.81
- P/E (TTM)
- -39.0
- EPS (TTM)
- -$3.26
Volume 1.12M
Average 0.94M
GKOS Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Glaukos CorporationNYSE: GKOS
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $28.87M rose 60.2% year over year, ahead of the +36.6% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 50.8% from the prior quarter. Over 3 fiscal years it compounded at +17.9% a year.
Context
- Stock-based compensation amounted to 12.5% of revenue in FY2025, down 0.6 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +60.2% holds above the trailing-twelve-month pace of +36.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 63.22M USD
- Year-over-year change
- +25.9%
- 4-year CAGR
- +20.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 63.22M | +25.9% |
| FY2024 | 2024-12-31 | 50.21M | +15.3% |
| FY2023 | 2023-12-31 | 43.53M | +12.9% |
| FY2022 | 2022-12-31 | 38.56M | +27.9% |
| FY2021 | 2021-12-31 | 30.15M | — |
Stock-Based Compensation vs competitors
How GKOS compares with its peers on the latest reported figures
- GKOS's LTM Jun 2026 stock-based compensation of $80.22M is the largest of the 9 companies compared; the peer median is $30.54M.
- Its year-over-year change of +36.6% is the highest of 8, against a peer median of -0.5%.
- Stock-based compensation amounts to 13.1% of revenue for GKOS, versus a peer median of 14.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $80.22M | +36.6% | +17.9% | 13.1% | |
| LTM Jun 2026 | $72M | -33.9% | +33.9% | 1.4% | |
| LTM Mar 2026 | $48.31M | +35.8% | +36.5% | 92.8% | |
| LTM Sep 2026 | $42M | -154.5% | +5.0% | 0.4% | |
| LTM Mar 2026 | $32.42M | +19.7% | +40.5% | 25.4% | |
| LTM Mar 2026 | $31.69M | -0.5% | +25.3% | 416.2% | |
| LTM Apr 2026 | $29.4M | +9.3% | +14.5% | 10.1% | |
| LTM Mar 2026 | $11.67M | -30.6% | +0.2% | 14.7% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $2.79M | — | — | — |
| Peer median (excluding GKOS) | $30.54M | -0.5% | +25.3% | 14.7% | |
Competitors are the stored peer set for GKOS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (49.59M) | (99.2M) | (134.66M) | (146.37M) | (133.66M) |
| Depreciation & Amortization | 34.42M | 35.95M | 37.98M | 39.92M | 42.35M |
| Deferred Income Tax | (1.03M) | (54K) | (120K) | (216K) | (6.49M) |
| Stock-Based Compensation | 30.15M | 38.56M | 43.53M | 50.21M | 63.22M |
| Change in Working Capital | 3.58M | (13.45M) | (10.13M) | (39.47M) | (31.55M) |
| Accounts Receivables | 1.7M | (3.14M) | (3.84M) | (21.97M) | (53.02M) |
| Inventory | (7.7M) | (15.47M) | (4.83M) | (18.79M) | 2.65M |
| Accounts Payables | 12.45M | 7.21M | 1.31M | 21K | 18.82M |
| Other Working Capital | (2.87M) | (2.05M) | (2.77M) | 1.26M | 0 |
| Other Non-Cash Items | 7.19M | 5.11M | 5.65M | 34.62M | 19.79M |
| Operating Cash Flow | 24.71M | (33.08M) | (57.76M) | (61.32M) | (46.34M) |
| Capital Expenditures | (47.79M) | (30.27M) | (20.25M) | (6.3M) | (7.67M) |
| Acquisitions (Net) | 3K | 151K | 0 | 38K | (12.44M) |
| Purchases of Investments | (215.29M) | (59.26M) | (265.59M) | (189.96M) | (232.29M) |
| Sales of Investments | 206.92M | 135.16M | 303.1M | 247.2M | 196.94M |
| Other Investing Activities | (2.08M) | (1.01M) | (3.17M) | (3.15M) | (22.16M) |
| Investing Cash Flow | (58.23M) | 44.78M | 14.1M | 47.83M | (77.61M) |
| Debt Repayment | (659K) | (527K) | (711K) | 51.34M | (1.12M) |
| Common Stock Issued | 30.94M | 9.21M | 19.03M | 46.76M | 21.14M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 8.98M | (2.43M) | (3.27M) | (6.56M) | (8.13M) |
| Financing Cash Flow | 39.26M | 6.25M | 15.04M | 91.54M | 11.89M |
| Effect of Forex Changes | (1.62M) | 870K | 2.56M | (1.89M) | 804K |
| Net Change in Cash | 4.11M | 18.82M | (26.06M) | 76.16M | (111.26M) |
| Free Cash Flow | (23.08M) | (63.35M) | (78.01M) | (67.62M) | (54.01M) |
Glaukos Corporation
NYSE:GKOS
Intrinsic Alpha fair value
Locked
Current Price
$233.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.